Shares of Novo Nordisk dropped over 24% after disappointing results in a trial for its CagriSema weight loss drug, which fell short of expectations with a 22.7% weight reduction. The stock recovered slightly to trade down 18.8%, while rival Eli Lilly’s obesity drug saw a 5% rise. Novo plans to further explore CagriSema’s potential after outperforming Wegovy in weight loss, with regulatory submission expected by 2025.
Full Article
Elon Musk endorses far-right Alternative for Germany party in upcoming election
Tesla CEO Elon Musk, a donor and adviser to President-elect Donald Trump, is now endorsing Germany's far-right Alternative for Germany (AfD) party, claiming that "only the AfD can save Germany." Musk made the statement while sharing a post from far-right influencer Naomi Seibt, who has promoted white nationalist ideology and denied climate change consensus. German Chancellor Olaf Scholz dismissed Musk's claim, as the AfD is currently polling in second place ahead of February elections, with...
Read more